Navigation Links
A Better Acetabular Solution from StelKast ... Naturally
Date:4/15/2011

MCMURRAY, Pa., April 15, 2011 /PRNewswire/ -- StelKast is proud to announce the recent FDA 510(k) clearance of their new EXp™ Acetabular Liners. EXp™, a blend of antioxidant and highly cross-linked polyethylene technology was developed with the consulting support of Steven Kurtz, Ph.D. and Exponent, Inc. (Philadelphia, PA). StelKast has also received 510(k) clearance for large diameter cobalt-chrome femoral heads and Biolox® delta femoral heads.

(Logo:  http://photos.prnewswire.com/prnh/20110415/LA83876LOGO)

Mr. Peter Stephans, Chairman & CEO, said in a statement, "EXp™ polyethylene technology represents an optimal blend of UHMWPE, the antioxidant vitamin E (alpha-tocopherol), and cross-linking for long-term oxidative stability, preservation of mechanical properties and performance. Unlike other highly cross-linked materials, EXp™ polyethylene requires no thermal processing or infusion of antioxidants to stabilize the material. The combination of EXp™ Acetabular Liners and large diameter heads promotes joint stability.

"StelKast is excited to be the first US orthopedic company to provide a highly crosslinked vitamin E blended acetabular system offering superior oxidation resistance. The introduction of EXp™ polyethylene is just another example of StelKast's commitment to place emerging technology and high quality implants in surgeon's hands through cost effective solutions."

Full commercial launch of the EXp™ Acetabular System is planned for July 2011. For inquiries, please contact your local StelKast representative or Customer Service at 888-273-1583.

StelKast specializes in the design, manufacture, and distribution of hip and knee implant systems. The Company's mission is to provide high-quality, cost effective solutions to meet the challenges of the orthopedic community through clinically proven design concepts and innovative technology. For more information about StelKast, please visit the company website at www.stelkast.com.

Source: StelKast Inc.
Ph 888.273.1583
Fax 724.941.5987
200 Hidden Valley Road
McMurray, PA 15317 USA
www.stelkast.com


'/>"/>
SOURCE StelKast Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
2. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
3. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
6. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
7. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Allergan plc, ... Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company ... therapies based upon tetracycline chemistry, announced that two ... treatment of moderate to severe acne met their ... once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory ...
(Date:3/27/2017)... , March 27, 2017 Cota ... for value-based precision medicine, today announced the ... Novartis Pharmaceuticals Corporation to help improve clinical ... As part of this agreement, ... collaboration entered into January 2016, teams from ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017 ... biopharmaceutical company focused on developing novel, small molecule drugs across ... Company,s President and Chief Executive Officer, will present a corporate ... April 4 at 3:40pm ET.  The conference will take place ... in New York , NY.  ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners and physician assistants ... increases in the healthcare workforce, according to a survey recently released by ... and candidate leads to healthcare employers of physicians and advanced practice clinicians. , ...
(Date:3/28/2017)... ... ... and fungi are probably not the first ingredients that come to mind when thinking about ... your diet can actually improve health outcomes. And the good news is they may be ... new peer-reviewed paper led by Maria Marco, Ph.D. , University of California, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for clear braces. People who want straight teeth without the extensive time ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually ...
(Date:3/27/2017)... ... 2017 , ... New patients who want to experience the benefits of ... them placed by Dr. Manju Kejriwal, with or without a referral. Dr. Kejriwal is ... accuracy of each dental implant placement. The i-CAT CBCT system captures the shapes of ...
(Date:3/27/2017)... UK (PRWEB) , ... March 27, 2017 , ... ... and ability to gain site attention and engagement over the household brands of ... webinar will discuss how partnering with the right outsourcing payments provider ...
Breaking Medicine News(10 mins):